A video interview with James C. Shehan, Chair of Lowenstein’s FDA Regulatory practice, on the FDA’s new approach to citizen petitions aimed at delaying market entry of products, was published on the CenterForBiosimilars.com. Shehan explains that the agency has issued more details on the criteria it will use in deciding whether a petition’s primary purpose is to delay generic competition.
Relevant Insights
-
PROFESSIONALS | Lawyers
Access the profiles of the more than 350 Lowenstein Sandler lawyers who provide critical legal counsel to clients in virtually every sector of the global economy...
-
NEWS & INSIGHTS | Firm News
Discover the latest updates and developments about Lowenstein Sandler...
-
NEWS & INSIGHTS | Publications
Access our insightful thought leadership, including articles, client alerts, and blog posts...